Henlius Ships First Batch of Serplulimab to India, Expanding Global Access to Innovative Cancer Treatment

Reuters

Aug 01

Henlius Ships First Batch of Serplulimab to India, Expanding Global Access to Innovative <a href="https://laohu8.com/S/CTHZ">Cancer Treatment</a>

Henlius, a subsidiary of Fosun International Limited, has successfully completed its first shipment of serplulimab to India. This anti-PD-1 monoclonal antibody, marketed under the trade name Hetronifly® in Europe, is now the first and only commercialized therapy in India for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). The product has been approved in nearly 40 countries and regions, covering close to half of the global population. This entry into the Indian market exemplifies Henlius' commitment to expanding global patient access to high-quality, innovative medicines. Since its launch, serplulimab has benefited over 110,000 patients globally. Henlius plans to continue leveraging its global capabilities in research, development, manufacturing, and commercialization to provide innovative treatments to patients worldwide.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fosun International Limited published the original content used to generate this news brief on August 01, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2556481177"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556481177\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556481177?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-01 22:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556481177","market":"us","top_or_hot":-1,"title":"Henlius Ships First Batch of Serplulimab to India, Expanding Global Access to Innovative Cancer Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Henlius Ships First Batch of Serplulimab to India, Expanding Global Access to Innovative <a href=\"https://laohu8.com/S/CTHZ\">Cancer Treatment</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Henlius, a subsidiary of Fosun International Limited, has successfully completed its first shipment of serplulimab to India. This anti-PD-1 monoclonal antibody, marketed under the trade name Hetronifly® in Europe, is now the first and only commercialized therapy in India for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). The product has been approved in nearly 40 countries and regions, covering close to half of the global population. This entry into the Indian market exemplifies Henlius' commitment to expanding global patient access to high-quality, innovative medicines. Since its launch, serplulimab has benefited over 110,000 patients globally. Henlius plans to continue leveraging its global capabilities in research, development, manufacturing, and commercialization to provide innovative treatments to patients worldwide.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fosun International Limited published the original content used to generate this news brief on August 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Henlius Ships First Batch of Serplulimab to India, Expanding Global Access to Innovative Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHenlius Ships First Batch of Serplulimab to India, Expanding Global Access to Innovative Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-01 22:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Henlius Ships First Batch of Serplulimab to India, Expanding Global Access to Innovative <a href=\"https://laohu8.com/S/CTHZ\">Cancer Treatment</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Henlius, a subsidiary of Fosun International Limited, has successfully completed its first shipment of serplulimab to India. This anti-PD-1 monoclonal antibody, marketed under the trade name Hetronifly® in Europe, is now the first and only commercialized therapy in India for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). The product has been approved in nearly 40 countries and regions, covering close to half of the global population. This entry into the Indian market exemplifies Henlius' commitment to expanding global patient access to high-quality, innovative medicines. Since its launch, serplulimab has benefited over 110,000 patients globally. Henlius plans to continue leveraging its global capabilities in research, development, manufacturing, and commercialization to provide innovative treatments to patients worldwide.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fosun International Limited published the original content used to generate this news brief on August 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00656","symbol_name":"复星国际","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250801:nNDL2WwKkK:1","article_id":"2556481177","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556481177","pubTimestamp":1754057060,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Henlius, a subsidiary of Fosun International Limited, has successfully completed its first shipment of serplulimab to India. This anti-PD-1 monoclonal antibody, marketed under the trade name Hetronifly in Europe, is now the first and only commercialized therapy in India for the first-line treatment of extensive-stage small cell lung cancer . The product has been approved in nearly 40 countries and regions, covering close to half of the global population. This entry into the Indian market exemplifies Henlius' commitment to expanding global patient access to high-quality, innovative medicines. Since its launch, serplulimab has benefited over 110,000 patients globally. Henlius plans to continue leveraging its global capabilities in research, development, manufacturing, and commercialization to provide innovative treatments to patients worldwide.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00656":"复星国际","BK1230":"工业集团企业","02696":"复宏汉霖","BK1161":"生物科技"},"translate_title":"复宏汉霖向印度运送首批Serplulimab，扩大全球创新癌症治疗的可及性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":0.9,"00656":0.9},"content_text":"Henlius Ships First Batch of Serplulimab to India, Expanding Global Access to Innovative Cancer Treatment\n\n\n        Henlius, a subsidiary of Fosun International Limited, has successfully completed its first shipment of serplulimab to India. This anti-PD-1 monoclonal antibody, marketed under the trade name Hetronifly® in Europe, is now the first and only commercialized therapy in India for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). The product has been approved in nearly 40 countries and regions, covering close to half of the global population. This entry into the Indian market exemplifies Henlius' commitment to expanding global patient access to high-quality, innovative medicines. Since its launch, serplulimab has benefited over 110,000 patients globally. Henlius plans to continue leveraging its global capabilities in research, development, manufacturing, and commercialization to provide innovative treatments to patients worldwide.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fosun International Limited published the original content used to generate this news brief on August 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}